The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial
Open accessAbstract
SUMMARY Background We conducted a prospective, randomised, double-blind trial to evaluate the efficacy of imatinib rechallenge in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) following objective progression of prior approved tyrosine kinase inhibitor (TKI) therapy. Method Between July 2010 and January 2013, 81 patients with prior benefit from first-line imatinib (initial response or stable disease for ≥6 months) and subsequent progression on at least imatinib and sunitinib were randomly assigned in a 1:1 ratio (by computer-generated randomisation list and the central coordinating center using telephone in a double-blind manner; randomised block permutation methods with block size of 2, 4, and 6; stratified by treatment line and performance status) to receive best supportive care with either imatinib 400 mg/day (n=41) or a placebo (n=40). At the time of disease progression, determined by the investigators, crossover to open-label imatinib was allowed. The primary endpoint was progression-free survival (PFS) determined by blinded external radiology review. Secondary endpoints included the disease control rate at 12 weeks, overall survival, and safety. All analyses were based on the full analysis set. This study is registered with ClinicalTrials.gov, number NCT01151852. Findings The median PFS was 1·8 months (95% confidence interval [CI], 1·7–3·6) with imatinib as compared with 0·9 months (95% CI, 0·9–1·7) with placebo (hazard ratio for progression or death, 0·46; 95% confidence interval [CI], 0·27–0·76; p=0·005, two-sided). In the placebo arm, 37 patients (93%) crossed over to open-label imatinib after progression. The most common grade 3 or higher adverse events of imatinib resumption was anemia (12 of 41, 29%), fatigue (four of 41, 10%), and hyperbilirubinemia (three of 41, 7%). Interpretation Despite prior resistance to imatinib, resumption of imatinib significantly improves PFS in GIST patients after disease progression on at least imatinib and sunitinib, demonstrating that residual bulk disease contains clones with continued sensitivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Self-citation
Cited by
Casali, P. G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brodowicz, T., Broto, J. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy095 · Cited by 750
Casali, P. G., Blay, J. Y., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.005 · Cited by 605
Nishida, T., Blay, J.-Y., Hirota, S., Kitagawa, Y., & Kang, Y.-K. (2016) · Gastric Cancer · doi:10.1007/s10120-015-0526-8 · Cited by 486
Self-citationGastrointestinal stromal tumours
Blay, J.-Y., Kang, Y.-K., Nishida, T., & von Mehren, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00254-5 · Cited by 460
Self-citationBlay, J.-Y., Serrano, C., Heinrich, M. C., Zalcberg, J., Bauer, S., Gelderblom, H., Schöffski, P., Jones, R. L., Attia, S., D'Amato, G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30168-6 · Cited by 416
Metadata
- Authors
- Kang, Y.-K., Ryu, M.-H., Yoo, C., Ryoo, B.-Y., Kim, H. J., Lee, J. J., Nam, B.-H., Ramaiya, N., Jagannathan, J., & Demetri, G. D.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 14
- Issue
- 12
- Pages
- 1175-1182
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W1982326378
- Cited by
- 191
- References
- 1
- FWCI
- 14.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(13)70453-4
- The paper
- Kang, Y.-K., Ryu, M.-H., Yoo, C., Ryoo, B.-Y., Kim, H. J., Lee, J. J., Nam, B.-H., Ramaiya, N., Jagannathan, J., & Demetri, G. D. (2013). Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(13)70453-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.